Spengler William Form 4 March 16, 2011

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

obligations may continue. See Instruction Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Spengler William

2. Issuer Name and Ticker or Trading

Issuer

5. Relationship of Reporting Person(s) to

Symbol

ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

(Check all applicable)

(Last) (First) (Middle) 3. Date of Earliest Transaction

(Zin)

(Month/Day/Year)

X_ Director 10% Owner Officer (give title Other (specify

C/O ENDO 03/14/2011

PHARMACEUTICALS, 100 ENDO

(Street)

BOULEVARD

(City)

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

CHADDS FORD, PA 19317

(City)	(State)	(Zıp)	Table I - Non-	Derivative Securitie	es Acquired, Disposed	Disposed of, or Beneficially Owned		
1.Title of	2. Transaction Da	ate 2A. Deemed	3.	4. Securities	5. Amount of	6. Ownership 7. Nature of		

1. Title of Transaction Date Security (Instr. 3)

ZA. Deemed (Month/Day/Year) Execution Date, if

(Month/Day/Year)

TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)

). Amount of Securities Beneficially Owned Following

6. Ownership Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4)

Reported (A) Transaction(s)

(Instr. 3 and 4)

Price Code V Amount (D)

2010 Stock Incentive

Plan

Restricted 03/14/2011 Α 4,260 Α (3) 4,260 D

Stock **Options** (RSU) (1) (2)

Common 03/14/2011 M 2,009 \$0 19,031 (5) D A (4)

Stock, par value, \$.01

1

Edgar Filing: Spengler William - Form 4

per share

Common

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	Secu Acqu (A) o Disp (D)	rities nired or osed of r. 3, 4,	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amoun or Number of Shares
2007 Stock Incentive Plan Restricted Stock Units (RSU)	<u>(1)</u>	03/14/2011		M			03/14/2011	03/14/2011(7)	Common Stock	2,009
2007 Stock Incentive Plan Restricted Stock	<u>(1)</u>	03/14/2011		A		1,417	03/14/2011	03/14/2011(8)	Common Stock	1,417

Reporting Owners

Units (RSU)

Reporting Owner Name / Address Relationships

Reporting Owners 2

Edgar Filing: Spengler William - Form 4

Director 10% Owner Officer Other

Spengler William C/O ENDO PHARMACEUTICALS 100 ENDO BOULEVARD CHADDS FORD, PA 19317



Signatures

/s/ Caroline B. Manogue, by Power of Attorney

03/16/2011

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo
- (1) Pharmaceuticals Holdings Inc. unless the director has elected to defer receipt of the vested shares under the Endo Pharmaceuticals Directors Deferred Compensation Plan.
- These restricted stock units (RSUs) generally vest 100% on March 14, 2012. Upon vesting, we consider the underlying RSUs to be expired. Pursuant to the Endo Pharmaceuticals Directors Deferred Compensation Plan, on November 30, 2010, Mr. Spengler elected to defer receipt of these RSUs.
- (3) These securities were granted to Mr. Spengler in consideration of his services on the Endo Pharmaceutical Holdings Inc. Board of Directors.
- This represents vesting of restricted stock units granted to Mr. Spengler on March 12, 2009. Upon each vesting date, each vested

 (4) restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc. On December 16, 2008, Mr. Spengler elected to defer receipt of these shares pursuant to the Endo Pharmaceuticals Directors Deferred Compensation Plan.
- This number represents (i) 5,677 restricted stock units (including the 4,260 restricted stock units granted above) and (ii) 13,354 shares of common stock, receipt of which 11,236 has been deferred under the Endo Pharmaceuticals Directors Deferred Compensation Plan. Mr. Spengler's beneficial ownership disclosed in this table excludes all shares held by Mr. Spengler indirectly, including shares underlying stock options.
- This represents vesting of restricted stock units granted to Mr. Spengler on March 12, 2010. Upon each vesting date, each vested

 (6) restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc. On December 15, 2009, Mr. Spengler elected to defer receipt of these shares pursuant to the Endo Pharmaceuticals Directors Deferred Compensation Plan.
- Fifty percent (50%) of Mr. Spengler's March 12, 2009 grant of restricted stock units (RSUs) generally vest on each of March 12, 2010 and March 12, 2011. Upon vesting, we consider the underlying RSUs to be expired. The 2,009 shown here is the amount that vested on March 14, 2011 (since March 12, 2011 was a Saturday). However, on December 16, 2008, Mr. Spengler elected to defer receipt of these shares pursuant to the Endo Pharmaceuticals Directors Deferred Compensation Plan.
- Fifty percent (50%) of Mr. Spengler's March 12, 2010 grant of restricted stock units (RSUs) generally vest on each of March 12, 2011 and March 12, 2012. Upon vesting, we consider the underlying RSUs to be expired. The 1,417 shown here is the amount that vested on March 14, 2011 (since March 12, 2011 was a Saturday). However, on December 15, 2009, Mr. Spengler elected to defer receipt of these shares pursuant to the Endo Pharmaceuticals Directors Deferred Compensation Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3